This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


2g56

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2g56.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:2g56.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2g56| PDB=2g56 | SCENE= }}
{{STRUCTURE_2g56| PDB=2g56 | SCENE= }}
-
'''crystal structure of human insulin-degrading enzyme in complex with insulin B chain'''
+
===crystal structure of human insulin-degrading enzyme in complex with insulin B chain===
-
==Overview==
+
<!--
-
Insulin-degrading enzyme (IDE), a Zn2+-metalloprotease, is involved in the clearance of insulin and amyloid-beta (refs 1-3). Loss-of-function mutations of IDE in rodents cause glucose intolerance and cerebral accumulation of amyloid-beta, whereas enhanced IDE activity effectively reduces brain amyloid-beta (refs 4-7). Here we report structures of human IDE in complex with four substrates (insulin B chain, amyloid-beta peptide (1-40), amylin and glucagon). The amino- and carboxy-terminal domains of IDE (IDE-N and IDE-C, respectively) form an enclosed cage just large enough to encapsulate insulin. Extensive contacts between IDE-N and IDE-C keep the degradation chamber of IDE inaccessible to substrates. Repositioning of the IDE domains enables substrate access to the catalytic cavity. IDE uses size and charge distribution of the substrate-binding cavity selectively to entrap structurally diverse polypeptides. The enclosed substrate undergoes conformational changes to form beta-sheets with two discrete regions of IDE for its degradation. Consistent with this model, mutations disrupting the contacts between IDE-N and IDE-C increase IDE catalytic activity 40-fold. The molecular basis for substrate recognition and allosteric regulation of IDE could aid in designing IDE-based therapies to control cerebral amyloid-beta and blood sugar concentrations.
+
The line below this paragraph, {{ABSTRACT_PUBMED_17051221}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 17051221 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_17051221}}
==About this Structure==
==About this Structure==
Line 26: Line 30:
[[Category: Tang, W J.]]
[[Category: Tang, W J.]]
[[Category: Protein-peptide complex]]
[[Category: Protein-peptide complex]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 04:41:59 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 04:44:12 2008''

Revision as of 01:44, 29 July 2008

Image:2g56.png

Template:STRUCTURE 2g56

crystal structure of human insulin-degrading enzyme in complex with insulin B chain

Template:ABSTRACT PUBMED 17051221

About this Structure

2G56 is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism., Shen Y, Joachimiak A, Rosner MR, Tang WJ, Nature. 2006 Oct 19;443(7113):870-4. Epub 2006 Oct 11. PMID:17051221

Page seeded by OCA on Tue Jul 29 04:44:12 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2g56"
Personal tools